Awards
Quotient Sciences wins Medilink UK Healthcare Business Award for Outstanding Achievement
Quotient Sciences has won the Outstanding Achievement Award at the 2019 Medilink UK Healthcare Business Awards.
6 / 59 articles displayed
-
-
Awards
Quotient Sciences wins Transatlantic Growth Award
Quotient Sciences announced that it has received a Transatlantic Growth Award at a ceremony hosted by BritishAmerican Business in London. The award, in the 'UK SME in the US' category, was presented to Gordon Cameron, CFO, Quotient Sciences.
-
News
Integrated Translational Pharmaceutics® Program conducted in U.S. With DRGT
Quotient Sciences, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceutics® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceutics program delivered from its U.S. operating facilities.
-
News
Quotient Sciences Increases Spray Drying Capabilities in the U.S.
Quotient Sciences, has invested in additional spray drying capabilities at its formulation development and clinical trial manufacturing facility in Garnet Valley, PA.
-
News
Quotient Sciences have made a number of submissions through the HRA/MHRA Combined Ways of Working Pilot
The HRA and MHRA have been exploring opportunities to improve the service being offered for the approval and ongoing management of Clinical Trials of Medicinal Products (CTIMPs) and launched a pilot to test an integrated process – the Combined Ways of Working Pilot.
-
News
Quotient Sciences Significantly Expands Formulation and Manufacturing in UK
Quotient Sciences, a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.